CTLA4 and cancer: Cancer immunotherapy has significantly transformed cancer treatment in recent decades, with immune checkpoint inhibitors (ICIs) like anti-PD(L)1 and anti-CTLA4 monoclonal antibodies revolutionizing treatment approaches and improving survival rates.